Основная статистика
| CIK | 1311241 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Intermolecular, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 30, 2019 |
IMI / Intermolecular, Inc. 15-12B - - FORM 15-12B Form 15-12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-35348 INTERMOLECULAR, INC. (Exact name of registrant as spe |
|
| September 24, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 9)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45882D 10 9 (CUSIP Number) STEVE WOLOSKY, ESQ. OLSH |
|
| September 23, 2019 |
IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No. |
|
| September 23, 2019 |
IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No. |
|
| September 23, 2019 |
IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No. |
|
| September 23, 2019 |
IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No. |
|
| September 23, 2019 |
IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No. |
|
| September 23, 2019 |
IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No. |
|
| September 23, 2019 |
IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No. |
|
| September 23, 2019 |
IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No. |
|
| September 23, 2019 |
IMI / Intermolecular, Inc. S-8 POS - - S-8 POS S-8 POS As filed with the Securities and Exchange Commission on September 23, 2019 Registration No. |
|
| September 20, 2019 |
Amended and Restated Bylaws of Intermolecular, Inc. EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BY-LAWS OF INTERMOLECULAR, INC. ARTICLE I STOCKHOLDERS SECTION 1.1. ANNUAL MEETINGS. An annual meeting of stockholders shall be held, either within or without the State of Delaware, on the last Friday of April of each year, beginning in the year 2020, for the purpose of electing directors and for the transaction of such other business as may come before the |
|
| September 20, 2019 |
Amended and Restated Certificate of Incorporation of Intermolecular, Inc. EX-3.1 Exhibit 3.1 EIGHTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF INTERMOLECULAR, INC. ARTICLE ONE The name of the corporation is Intermolecular, Inc. (the “Corporation”). ARTICLE TWO The address of the Corporation’s registered office in the State of Delaware is 251 Little Falls Drive, Wilmington, Delaware 19808, New Castle County. The name of its registered agent at that address is C |
|
| September 20, 2019 |
Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 20, 2019 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 14, 2019 |
EX-99.1 2 tv527504ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing on their behalf of Amendment No. 1 to Schedule 13D and any amendments thereto, with respect to the shares of Common Stock, par value $0.001 per share, of Intermole |
|
| August 14, 2019 |
IMI / Intermolecular, Inc. / Merck Kgaa - SC 13D/A Activist Investment SC 13D/A 1 tv527504sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) INTERMOLECULAR, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D109 (CUSIP Number) David A. Martland, Esq. Nixon Peabody LLP 53 State Street Boston, MA 02109 (617) |
|
| August 8, 2019 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2019 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 8, 2019 |
Intermolecular Reports Second Quarter 2019 Financial Results Exhibit 99.1 Intermolecular Reports Second Quarter 2019 Financial Results SAN JOSE, Calif., August 8, 2019 - Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanced materials innovation, today reported results for its second quarter ended June 30, 2019. Second Quarter of 2019 Financial Results Revenue for the second quarter of 2019 was $4.6 million, a decrease of 31% from $6.7 million |
|
| August 8, 2019 |
IMI / Intermolecular, Inc. 10-Q - Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35348 Intermolecu |
|
| July 17, 2019 |
EX-99.1 Exhibit 99.1 News Release July 17, 2019 Intermolecular Stockholders Approve Merck KGaA, Darmstadt, Germany’s Proposed Acquisition of Intermolecular SAN JOSE, California, July 17, 2019 — Intermolecular, Inc. (NASDAQ: IMI) announced today that the stockholders of Intermolecular have approved the previously announced proposed acquisition of all outstanding shares of common stock of Intermolec |
|
| July 17, 2019 |
Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders 8-K 1 d766472d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 17, 2019 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incor |
|
| June 28, 2019 |
IMI / Intermolecular, Inc. DEFA14A - - DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A (RULE 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, fo |
|
| June 12, 2019 |
IMI / Intermolecular, Inc. DEFM14A - - DEFINITIVE PROXY STATEMENT PERTAINING TO A MERGER DEFINITIVE PROXY STATEMENT PERTAINING TO A MERGER Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 28, 2019 |
IMI / Intermolecular, Inc. PREM14A - - PRELIMINARY PROXY STATEMENT PERTAINING TO A MERGER Preliminary Proxy Statement pertaining to a Merger Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| May 16, 2019 |
IMI / Intermolecular, Inc. / Merck Kgaa - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) INTERMOLECULAR, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D109 (CUSIP Number) David A. Martland, Esq. Nixon Peabody LLP 53 State Street Boston, MA 02109 (617) 345-1000 (Name, Address and Telephone Nu |
|
| May 16, 2019 |
IMI / Intermolecular, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorize |
|
| May 16, 2019 |
EXHIBIT 99.1 Joint Filing Agreement In accordance with Rule 13d-1(k) promulgated under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing on their behalf of a single Schedule 13D and any amendments thereto, with respect to the shares of Common Stock, par value $0.001 per share, of Intermolecular, Inc. and further agrees that this Joint Filin |
|
| May 14, 2019 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 14, 2019 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 14, 2019 |
Intermolecular Reports First Quarter 2019 Financial Results Exhibit 99.1 Intermolecular Reports First Quarter 2019 Financial Results SAN JOSE, Calif., May 14, 2019 - Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanced materials innovation, today reported results for its first quarter ended March 31, 2019. Q1 2019 Financial and Operational Highlights • Program revenue totaled $6.4 million or 96% of total revenue of $6.7 million. • Gross pro |
|
| May 14, 2019 |
IMI / Intermolecular, Inc. 10-Q Quarterly Report 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35348 Intermolec |
|
| May 7, 2019 |
begin 644 ex991to13da807738042050719.pdf M)5!$1BTQ+C4-)>+CS],-"C@U(# @;V)J#3P\+TQI;F5A%LX-2 S M-UTO26YF;R X-" P(%(O3&5N9W1H(#$P,2]07!E+UA2968O5ULQ(#,@,5T^/G-T\U& MATP7\DX0K ":T58]/7IWYG\NLLS(GYX6H;FQH:4;%TX+ M@8EES[=BBPRZ<=VNA&O:L9T/@1)F)3R;EF[7!E+T-A=&%L;V<^ M/@UE;F1O8FH-.#<@,"!O8FH-/#PO07)T0F]X6S @," V,3(@-SDR72]";&5E M9$)O>%LP(# @-C$R(#%LP(# @-C$R(#%LP(# @ M-C$R(#3BD)PM6=+F+5J=)=P# M#">GU;H%Y7S |
|
| May 7, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 8)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45882D 10 9 (CUSIP Number) STEVE WOLOSKY, ESQ. OLSH |
|
| May 6, 2019 |
IMI / Intermolecular, Inc. DEFA14A DEFA14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (RULE 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission |
|
| May 6, 2019 |
IMI / Intermolecular, Inc. DFAN14A DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ¨ Filed by a Party other than the Registrant x Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e) |
|
| May 6, 2019 |
EX-2.2 Exhibit 2.2 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT COMPANY STOCKHOLDER SUPPORT AGREEMENT, dated as of [●], 2019 (this “Agreement”), by and between EMD Group Holding II, Inc., a Delaware corporation (“Parent”), and the stockholder identified on the signature pages hereto (the “Stockholder”). WHEREAS, concurrently herewith, Intermolecular, Inc., a Delaware corporation (“Indigo”), EMD P |
|
| May 6, 2019 |
3011 N. First Street, San Jose, CA 95134 EX-99.3 Exhibit 99.3 May 6, 2019 Dear [ Customer Name ]: We are pleased to announce today that Intermolecular (“IMI”) has entered into a definitive agreement pursuant to which IMI will become a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany (“Merck KGaA”). As a result of the planned integration of these leading technology innovators, the two companies expect to be able to provide a more |
|
| May 6, 2019 |
EX-2.1 2 d666010dex21.htm EX-2.1 Table of Contents Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among EMD GROUP HOLDING II, INC., EMD PERFORMANCE MATERIALS SEMICONDUCTOR SERVICES CORP. and INTERMOLECULAR, INC. Dated as of May 6, 2019 Table of Contents TABLE OF CONTENTS Page ARTICLE I THE MERGER 1 1.1 The Merger 1 1.2 The Effective Time 2 1.3 The Closing 2 1.4 Effect of the |
|
| May 6, 2019 |
EX-99.2 5 d666010dex992.htm EX-99.2 Exhibit 99.2 Email to All-Company from CEO Chris Kramer IMPORTANT: Please read & attend a Company All-Hands meeting at 11:00 AM (PDT) Dear Colleagues, In our time together at IMI, you and I have repeatedly addressed many challenges to make our company better and to help achieve our objectives. You have embraced our PACE values and handled change with courage and |
|
| May 6, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 Intermolecular, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35348 20-1616267 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2019 |
EX-99.1 Exhibit 99.1 News Release May 6, 2019 Intermolecular to be acquired by Merck KGaA, Darmstadt, Germany for $1.20 per share in an all cash transaction • Acquisition to strengthen technology offering and diversify performance materials portfolio of Merck KGaA, Darmstadt, Germany • Transaction expected to close in the second half of 2019 San Jose, California, May 6, 2019 – Intermolecular, Inc. |
|
| May 6, 2019 |
Letter to Intermolecular employees, dated as of May 6, 2019 EX-99.2 Exhibit 99.2 Email to All-Company from CEO Chris Kramer IMPORTANT: Please read & attend a Company All-Hands meeting at 11:00 AM (PDT) Dear Colleagues, In our time together at IMI, you and I have repeatedly addressed many challenges to make our company better and to help achieve our objectives. You have embraced our PACE values and handled change with courage and confidence. Today we are an |
|
| May 6, 2019 |
EX-2.1 Table of Contents Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among EMD GROUP HOLDING II, INC., EMD PERFORMANCE MATERIALS SEMICONDUCTOR SERVICES CORP. and INTERMOLECULAR, INC. Dated as of May 6, 2019 Table of Contents TABLE OF CONTENTS Page ARTICLE I THE MERGER 1 1.1 The Merger 1 1.2 The Effective Time 2 1.3 The Closing 2 1.4 Effect of the Merger 2 1.5 Certificate |
|
| May 6, 2019 |
IMI / Intermolecular, Inc. DEFA14A 8-K 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2019 Intermolecular, Inc. (Exact name of registrant as specified in its charter) Delaware 001-35348 20-1616267 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 6, 2019 |
EX-2.2 Exhibit 2.2 FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENT COMPANY STOCKHOLDER SUPPORT AGREEMENT, dated as of [●], 2019 (this “Agreement”), by and between EMD Group Holding II, Inc., a Delaware corporation (“Parent”), and the stockholder identified on the signature pages hereto (the “Stockholder”). WHEREAS, concurrently herewith, Intermolecular, Inc., a Delaware corporation (“Indigo”), EMD P |
|
| May 6, 2019 |
Press Release issued by Intermolecular, Inc. on May 6, 2019 EX-99.1 Exhibit 99.1 News Release May 6, 2019 Intermolecular to be acquired by Merck KGaA, Darmstadt, Germany for $1.20 per share in an all cash transaction • Acquisition to strengthen technology offering and diversify performance materials portfolio of Merck KGaA, Darmstadt, Germany • Transaction expected to close in the second half of 2019 San Jose, California, May 6, 2019 – Intermolecular, Inc. |
|
| May 6, 2019 |
Letter to Intermolecular customers, dated as of May 6, 2019 EX-99.3 Exhibit 99.3 May 6, 2019 Dear [ Customer Name ]: We are pleased to announce today that Intermolecular (“IMI”) has entered into a definitive agreement pursuant to which IMI will become a wholly owned subsidiary of Merck KGaA, Darmstadt, Germany (“Merck KGaA”). As a result of the planned integration of these leading technology innovators, the two companies expect to be able to provide a more |
|
| April 29, 2019 |
IMI / Intermolecular, Inc. 10-K/A (Annual Report) 10-K/A 10-K/A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 3, 2019 |
IMI / Intermolecular, Inc. / Subin Neil S - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) March 29, 2019 (Date of Event which Requires |
|
| April 2, 2019 |
SC 13D/A 1 sc13da70773804204022019.htm AMENDMENT NO. 7 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 7)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of C |
|
| April 2, 2019 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Intermolecular, Inc. This Joint Filing Agreement shall be filed as an Exhib |
|
| March 8, 2019 |
IMI / Intermolecular, Inc. S-8 S-8 1 imi-s8.htm S-8 As filed with the Securities and Exchange Commission on March 8, 2019 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTERMOLECULAR, INC. (Exact name of registrant as specified in its charter) Delaware 20-1616267 (State or other jurisdiction of incorporation or organ |
|
| March 8, 2019 |
IMI / Intermolecular, Inc. 10-K (Annual Report) 10-K 1 imi-10k20181231.htm 10-K Of UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission fi |
|
| February 12, 2019 |
Results of Operations and Financial Condition 8-K 1 imi-8k20190212.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2019 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In |
|
| February 12, 2019 |
Exhibit 99.1 Intermolecular Reports Fourth Quarter and Full Year 2018 Financial Results 2018 Marked First Full Year of Positive Adjusted EBITDA Since 2013 Positive Operating Cash Flow of $5.9 million in 2018 SAN JOSE, Calif., February 12, 2019 - Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanced materials innovation, today reported results for the fourth quarter and full year end |
|
| February 8, 2019 |
IMI / Intermolecular, Inc. / U S Venture Partners IX L P - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv512571sc13ga.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 6)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2018 ( |
|
| February 1, 2019 |
IMI / Intermolecular, Inc. / Presidio Partners 2014, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d698243dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4)* Intermolecular, Inc. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2018 (Date of Event Which Requires Filing of this Statement) Check t |
|
| December 28, 2018 |
8-K 1 d679096d8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 26, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 (State or Other Jurisdiction of Incorporation) (C |
|
| November 6, 2018 |
Exhibit 99.1 Intermolecular Reports Third Quarter and Nine Month 2018 Financial Results Fifth Consecutive Quarter of Positive Adjusted EBITDA; Secured Major New Program Service Agreement with New Leading Semiconductor Manufacturer; Board of Directors Approves $10 Million Share Repurchase Program SAN JOSE, Calif., November 6, 2018 - Intermolecular, Inc. (Nasdaq: IMI), the trusted partner for advanc |
|
| November 6, 2018 |
Results of Operations and Financial Condition 8-K 1 imi-8k20181102.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inc |
|
| November 6, 2018 |
IMI / Intermolecular, Inc. 10-Q (Quarterly Report) 10-Q 1 imi-10q20180930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| August 6, 2018 |
Exhibit 99.1 Intermolecular Reports Second Quarter 2018 Financial Results Program Revenue Up 45% Year-over-Year, Driving Net Income of $0.5 million and 19% Adjusted EBITDA Margin SAN JOSE, Calif., August 6, 2018 - Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today reported results for its second quarter ended June 30, 2018. Q2 2018 Financial and Operat |
|
| August 6, 2018 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 6, 2018 |
IMI / Intermolecular, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35348 Intermolecu |
|
| May 25, 2018 |
Submission of Matters to a Vote of Security Holders 8-K 1 imi-8k20180524.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpo |
|
| May 11, 2018 |
8-K 1 imi-8k20180515.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 09, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpo |
|
| May 8, 2018 |
Results of Operations and Financial Condition 8-K 1 imi-8k20180508.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 8, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpor |
|
| May 8, 2018 |
Exhibit 99.1 Intermolecular Reports First Quarter 2018 Financial Results Company Achieves Third Consecutive Quarter of Positive Adjusted EBITDA SAN JOSE, Calif., May 8, 2018 - Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today reported results for its first quarter ended March 31, 2018. Q1 2018 Financial and Operational Highlights • Total revenue of $9 |
|
| May 8, 2018 |
IMI / Intermolecular, Inc. 10-Q (Quarterly Report) 10-Q 1 imi-10q20180331.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2018 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| April 10, 2018 |
IMI / Intermolecular, Inc. DEFA14A DEFA14A 1 imi-defa14a20171231.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 10, 2018 |
IMI / Intermolecular, Inc. DEF 14A DEF 14A 1 imi-def14a20180524.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| March 2, 2018 |
IMI / Intermolecular, Inc. S-8 As filed with the Securities and Exchange Commission on March 2, 2018 Registration No. |
|
| March 2, 2018 |
IMI / Intermolecular, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2017 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35348 Intermolecular |
|
| February 13, 2018 |
EX-99.1 2 imi-ex9916.htm EX-99.1 Exhibit 99.1 Intermolecular Reports Fourth Quarter and Full Year 2017 Financial Results SAN JOSE, Calif., February 13, 2018 - Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today reported results for its fourth quarter and full year ended December 31, 2017. Results Highlights: • Fourth quarter total revenue of $10.5 milli |
|
| February 13, 2018 |
Results of Operations and Financial Condition 8-K 1 imi-8k20180213.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 13, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In |
|
| February 12, 2018 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 8, 2018 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 12, 2018 |
IMI / Intermolecular, Inc. / Presidio Partners 2014, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d519666dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Intermolecular, Inc. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2017 (Date of Event Which Requires Filing of this Statement) Check t |
|
| January 31, 2018 |
IMI / Intermolecular, Inc. / U S Venture Partners IX L P - SC 13G/A Passive Investment SC 13G/A 1 tv483954sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 5)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2017 (Date o |
|
| January 23, 2018 |
IMI / Intermolecular, Inc. / Subin Neil S - SC 13G Passive Investment SC 13G 1 tv483742sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) January 12, 2 |
|
| November 2, 2017 |
Intermolecular 10-Q (Quarterly Report) 10-Q 1 imi-10q20170930.htm 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2017 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commiss |
|
| November 2, 2017 |
EX-99.1 2 imi-ex9916.htm EX-99.1 Exhibit 99.1 Intermolecular Announces Third Quarter 2017 Financial Results SAN JOSE, Calif., November 2, 2017 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its Third Quarter ended September 30, 2017. Results Highlights: • Positive third quarter adjusted EBITDA on 7% sequential revenue growth • Third quarter total revenue of $8.6 million • Five new |
|
| November 2, 2017 |
Results of Operations and Financial Condition imi-8k20171102.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation |
|
| November 2, 2017 |
imi-8k20171031.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation |
|
| October 10, 2017 |
8-K 1 imi-8k20171009.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 9, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco |
|
| September 5, 2017 |
8-K 1 imi-8k20170904.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 04, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of I |
|
| August 25, 2017 |
CORRESP August 25, 2017 VIA FEDERAL EXPRESS United States Securities and Exchange Commission Division of Corporation Finance Mail Stop 3030 Washington, D. |
|
| August 8, 2017 |
Intermolecular 10-Q (Quarterly Report) imi-10q20170630.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2017 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0 |
|
| August 8, 2017 |
Results of Operations and Financial Condition 8-K 1 imi-8k20170808.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 8, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incor |
|
| August 8, 2017 |
imi-ex9916.htm Exhibit 99.1 Intermolecular Announces Second Quarter 2017 Financial Results SAN JOSE, Calif., August 8, 2017 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its Second Quarter ended June 30, 2017. Results Highlights: • Second quarter total revenue of $8.1 million • Three new customer contracts signed during the quarter • Net cash position remains strong at $27.0 mill |
|
| May 17, 2017 |
Submission of Matters to a Vote of Security Holders 8-K 1 imi-8k20170516.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpo |
|
| May 15, 2017 |
IMI / Intermolecular, Inc. / Miller Lloyd I III - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) May 11, 2017 (Date of Event which Requires F |
|
| May 4, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 4, 2017 |
Intermolecular IMI-Q1-20170331 (Quarterly Report) 10-Q 1 imi-10q20170331.htm IMI-Q1-20170331 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2017 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| May 4, 2017 |
Results of Operations and Financial Condition imi-8k20170504.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 4, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Co |
|
| May 4, 2017 |
imi-ex9916.htm Exhibit 99.1 Intermolecular Announces First Quarter 2017 Financial Results SAN JOSE, Calif., May 4, 2017 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its first Quarter ended March 31, 2017. Results Highlights: • First quarter total revenue of $9.9 million • Implemented cost reductions to enable positive Adjusted EBITDA at $10 million revenue per quarter • New cust |
|
| May 4, 2017 |
Separation Agreement by and between Intermolecular, Inc. and C. Richard Neely, Jr Exhibit 10.4 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between C. Richard Neely, Jr. (“Executive”) and Intermolecular, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A.Executive’s employment with the Company and st |
|
| May 4, 2017 |
Separation Agreement by and between Intermolecular, Inc. and Bruce McWilliams. Exhibit 10.3 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between Dr. Bruce M. McWilliams (“Executive”) and Intermolecular, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A.Executive’s employment with the Company and |
|
| May 4, 2017 |
Amended and Restated Change in Control and Severance Agreement EX-10.1 2 imi-ex101220.htm EX-10.1 Exhibit 10.1 INTERMOLECULAR, INC. AMENDED AND RESTATED CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Amended and Restated Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Bill Roeschlein (“Executive”) and Intermolecular, Inc. (the “Company”), effective as of April 3, 2017 (the “Effective Date”). R E C I T A L S |
|
| May 4, 2017 |
Offer Letter by and between Intermolecular, Inc. and Bill Roeschlein EX-10.2 3 imi-ex102219.htm EX-10.2 Exhibit 10.2 March 29, 2017 Bill Roeschlein Intermolecular, Inc. 3011 N. First Street San Jose, CA 95134 Dear Bill: On behalf of Intermolecular, Inc. (the “Company”), I set forth the certain terms of your updated employment with the Company: 1.Effective April 3, 2017, you will serve on a full-time basis as the Company’s Chief Financial Officer and principal finan |
|
| April 11, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 10, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 5, 2017 |
DEFA14A 1 imi-defa14a20170516.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 5, 2017 |
DEF 14A 1 imi-def14a20170516.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only ( |
|
| March 30, 2017 |
EX-99.1 2 ex991to13da607738042033017.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Intermolecu |
|
| March 30, 2017 |
SC 13D/A 1 sc13da60773804203302017.htm AMENDMENT NO. 6 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 6)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of C |
|
| March 29, 2017 |
Intermolecular FORM 8-K (Current Report/Significant Event) Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 3, 2017 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTERMOLECULAR, INC. (Exact name of registrant as specified in its charter) Delaware 20-1616267 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3011 N. First Street San Jose, CA 95134 (A |
|
| March 3, 2017 |
Intermolecular 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2016 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35348 Intermolecular |
|
| March 1, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 13, 2017 |
IMI / Intermolecular, Inc. / Presidio Partners 2014, L.P. - SC 13G/A Passive Investment SC 13G/A 1 d345799dsc13ga.htm SC 13G/A CUSIP No. 45882D109 Page 1 of 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Intermolecular, Inc. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2016 (Date of Event Which Requires |
|
| February 13, 2017 |
IMI / Intermolecular, Inc. / U S Venture Partners IX L P - SC 13G/A Passive Investment SC 13G/A 1 v458831sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2016 (Date of |
|
| February 10, 2017 |
IMI / Intermolecular, Inc. / Cowen Prime Services LLC Passive Investment SC 13G 1 s22-1771213g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2016 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 9, 2017 |
Results of Operations and Financial Condition 8-K 1 imi-8k20170209.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 9, 2017 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inc |
|
| February 9, 2017 |
EX-99 2 imi-ex996.htm EX-99 Exhibit 99.1 Intermolecular Announces Fourth Quarter 2016 and Full Year 2016 Financial Results SAN JOSE, Calif., February 9, 2017 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its fourth quarter and full year ended December 31, 2016. Results Highlights: • Fourth quarter total revenue of $10.5 million; 2016 fiscal year revenue of $47.3 million, with 201 |
|
| January 30, 2017 |
Intermolecular SC 13G/A (Passive Acquisition of More Than 5% of Shares) SC 13G/A 1 v457592sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) Decemb |
|
| December 22, 2016 |
8-K 1 imi-8k20161222.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 17, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In |
|
| November 17, 2016 |
SC 13D/A 1 sc13da50773804211172016.htm AMENDMENT NO. 5 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 5)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of C |
|
| November 16, 2016 |
Governance Agreement by and between Intermolecular, Inc. and Raging Capital Management, LLC imi-ex10143.htm Exhibit 10.1 GOVERNANCE AGREEMENT This GOVERNANCE AGREEMENT is made and entered into as of November 14, 2016 (the ?Agreement?) by and between Intermolecular, Inc., a Delaware corporation (the ?Company?), and Raging Capital Management, LLC, a Delaware limited liability company (the ?Investor?). The Company and the Investor are referred to herein as the ?Parties.? WHEREAS, the Invest |
|
| November 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 14, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 4)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45882D 10 9 (CUSIP Number) STEVE WOLOSKY, ESQ. OLSH |
|
| November 14, 2016 |
Exhibit 99.1 GOVERNANCE AGREEMENT This GOVERNANCE AGREEMENT is made and entered into as of November 14, 2016 (the “Agreement”) by and between Intermolecular, Inc., a Delaware corporation (the “Company”), and Raging Capital Management, LLC, a Delaware limited liability company (the “Investor”). The Company and the Investor are referred to herein as the “Parties.” WHEREAS, the Investor beneficially |
|
| November 2, 2016 |
Intermolecular IMI-Q3-20160930 (Quarterly Report) 10-Q 1 imi-10q20160930.htm IMI-Q3-20160930 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2016 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from |
|
| November 2, 2016 |
imi-ex9916.htm Exhibit 99.1 Intermolecular Announces Third Quarter 2016 Financial Results SAN JOSE, Calif., November 2, 2016 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its third quarter of fiscal 2016 ended September 30, 2016. Results Highlights: ? Third quarter total revenue finished at $10.6 million, with program revenue growing 2% year-over-year ? Significant cost reduction |
|
| November 2, 2016 |
Intermolecular 8-K (Current Report/Significant Event) imi-8k20161102.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation |
|
| November 2, 2016 |
Separation Agreement by and between Intermolecular, Inc. and Scot A. Griffin. Exhibit 10.30 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between Scot A. Griffin (“Executive”) and Intermolecular, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A.Executive’s employment with the Company and status |
|
| November 2, 2016 |
Change in Control and Severance Agreement between Intermolecular, Inc. and Christian Kramer Exhibit 10.11d INTERMOLECULAR, INC. CHANGE IN CONTROL AND SEVERANCE AGREEMENT This Change in Control and Severance Agreement (the “Agreement”) is made and entered into by and between Christian Kramer (“Executive”) and Intermolecular, Inc. (the “Company”), effective as of the date of the closing of the Company’s initial public offering of shares of its common stock (the “Effective Date”). R E C I T |
|
| November 2, 2016 |
3011 North First Street, San Jose, CA 95134 (408) 582-5700 / (408) 582-5179 fax Exhibit 10.29 July 27, 2016 Christian Kramer [home address] Re:Intermolecular, Inc. Offer Letter Dear Chris: Intermolecular, Inc. (the “Company”) is pleased to formally extend to you an offer of employment for the position of Chief Executive Officer and President, reporting to the Bruce McWilliams, Executive Chairman. You will be based at Company’s offices in San Jose, California. To compensate yo |
|
| September 22, 2016 |
8-K 1 imi-8k20160916.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 16, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of I |
|
| August 11, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 3)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45882D 10 9 (CUSIP Number) STEVE WOLOSKY, ESQ. OLSH |
|
| August 4, 2016 |
Intermolecular IMI-Q2-20160630 (Quarterly Report) 10-Q 1 imi-10q20160630.htm IMI-Q2-20160630 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2016 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to C |
|
| August 4, 2016 |
Results of Operations and Financial Condition 8-K 1 d221263d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 4, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco |
|
| August 4, 2016 |
Intermolecular Appoints Chris Kramer President and CEO Bruce McWilliams becomes Executive Chairman EX-99.2 3 d221263dex992.htm EX-99.2 Exhibit 99.2 Intermolecular Appoints Chris Kramer President and CEO Bruce McWilliams becomes Executive Chairman SAN JOSE, Calif., August 4, 2016 — Intermolecular, Inc. (NASDAQ: IMI), the trusted partner for advanced materials innovation, today announced that Chris Kramer has been appointed as President and Chief Executive Officer reporting to Bruce McWilliams, w |
|
| August 4, 2016 |
EX-99.1 2 d221263dex991.htm EX-99.1 Exhibit 99.1 Intermolecular Announces Second Quarter 2016 Financial Results SAN JOSE, Calif., August 4, 2016 — Intermolecular, Inc. (NASDAQ: IMI) today reported results for its second quarter of fiscal 2016 ended June 30, 2016. Results Highlights: • Second quarter revenue of $11.7 million, 7% year-over-year growth, 39% year-over-year program revenue growth • Tot |
|
| May 27, 2016 |
Submission of Matters to a Vote of Security Holders 8-K 1 imi-20160525x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorp |
|
| May 27, 2016 |
SC 13D/A 1 sc13da20773804205252016.htm AMENDMENT NO. 2 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 2)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of C |
|
| May 27, 2016 |
EX-99.1 2 ex991to13da207738042052516.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Intermolecu |
|
| May 5, 2016 |
Intermolecular 10-Q (Quarterly Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2016 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00 |
|
| May 5, 2016 |
Results of Operations and Financial Condition 8-K 1 imi-20160505x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 5, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpo |
|
| May 5, 2016 |
imiEx991 Exhibit 99.1 Intermolecular Announces First Quarter 2016 Financial Results SAN JOSE, Calif., May 5, 2016 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its first quarter of fiscal 2016 ended March 31, 2016. Results Highlights: ? First quarter revenue of $14.5 million, 47% year-over-year growth ? Second consecutive quarter of positive EBITDA First Quarter Fiscal 2016 Resul |
|
| April 12, 2016 |
DEFA14A 1 imi-20160525xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only |
|
| April 12, 2016 |
imiCurrent folioDEF14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 11, 2016 |
EX-99.1 2 ex991to13da107738042041116.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Intermolecu |
|
| April 11, 2016 |
SC 13D/A 1 sc13da10773804204112016.htm AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of C |
|
| April 1, 2016 |
EX-16.1 2 c241-20160401ex161b0f3be.htm EX-16.1 Exhibit 16.1 April 1, 2016 Securities and Exchange Commission Washington, D.C. 20549 Ladies and Gentlemen: We were previously principal accountants for Intermolecular, Inc. and, under the date of March 28, 2016, we reported on the consolidated financial statements of Intermolecular, Inc. as of and for the years ended December 31, 2015 and 2014, and th |
|
| April 1, 2016 |
8-K 1 c241-20160401x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 1, 2016 (March 29, 2016) Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jur |
|
| March 28, 2016 |
S-8 1 imi-20160328xs8.htm S-8 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTERMOLECULAR, INC. (Exact name of registrant as specified in its charter) Delaware 20-1616267 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3011 N. Firs |
|
| March 28, 2016 |
Intermolecular Files Fiscal Year 2015 Financial Statements EX-99.1 2 imi-20160328ex99122e718.htm EX-99.1 Exhibit 99.1 Intermolecular Files Fiscal Year 2015 Financial Statements SAN JOSE, Calif., March 28, 2016 - Intermolecular, Inc. (NASDAQ: IMI) today filed its annual report on Form 10-K for the full year ended December 31, 2015. The Company’s Form 10-K reports fourth quarter and annual revenues of $13.0 million and $45.3 million, respectively, instead o |
|
| March 28, 2016 |
8-K 1 imi-20160328x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 28, 2016 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco |
|
| March 28, 2016 |
Intermolecular 10-K (Annual Report) Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2015 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35 |
|
| February 10, 2016 |
IMI / Intermolecular, Inc. / Presidio Partners 2014, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO §240.13d-2 Amendment No. #1 INTERMOLECULAR, INC. (Name of Issuer) COMMON STOCK, $.001 PAR VALUE (Title of Class of Securities) 45882D109 (CUSIP Number) DECEMBER 31, 2015 (Da |
|
| February 9, 2016 |
IMI / Intermolecular, Inc. / Cowen Prime Services LLC - SCHEDULE 13G Passive Investment SC 13G 1 s22-1661713g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2015 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 4, 2016 |
imiEx991 Exhibit 99.1 Intermolecular Reports Fourth Quarter 2015 and Full Year 2015 Financial Results Results Highlights: · Positive fourth quarter operating cash flow · Fourth quarter revenue of $13.5 million, 17% quarter-on-quarter growth SAN JOSE, Calif., February 4, 2016 - Intermolecular, Inc. (NASDAQ: IMI) today reported results for its fourth quarter and full year ended December 31, 2015. Fo |
|
| February 4, 2016 |
Results of Operations and Financial Condition imiCurrent folio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 3, 2016 |
IMI / Intermolecular, Inc. / U S Venture Partners IX L P - SC 13G/A Passive Investment SC 13G/A 1 v430377sc13g-a.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 3)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D 109 (CUSIP Number) December 31, 2015 (Date |
|
| February 2, 2016 |
IMI / Intermolecular, Inc. / Miller Lloyd I III - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2015 (Date of Event which Requi |
|
| November 23, 2015 |
Intermolecular 8-K (Current Report/Significant Event) imiCurrent folio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 23, 2015 |
EX-99.1 2 imi-20151117ex991997938.htm EX-99.1 Exhibit 99.1 Intermolecular Announces New Developments in Its Relationship with Micron SAN JOSE, Calif., November 23, 2015 - Intermolecular, Inc. (NASDAQ: IMI) - a leader in engineered materials solutions - today announced that its Collaborative Development Program (“CDP”) agreement with Micron Technology, Inc. (“Micron”) will conclude on April 1, 2016 |
|
| November 6, 2015 |
November 05, 2015, Intermolecular, Inc. Q3 Earnings Call EX-99.2 3 imi-20151105ex992a0c27e.htm EX-99.2 November 05, 2015, Intermolecular, Inc. Q3 Earnings Call CORPORATE PARTICIPANTS Rick Neely Intermolecular, Inc. - SVP & CFO Bruce McWilliams Intermolecular, Inc. - President & CEO CONFERENCE CALL PARTICIPANTS Edwin Mok Needham & Company - Analyst Gus Richard Northland Capital Markets - Analyst PRESENTATION Operator Good day, ladies and gentlemen, and w |
|
| November 6, 2015 |
EX-99.1 2 imi-20151105ex991a3e2a0.htm EX-99.1 Exhibit 99.1 Intermolecular Announces Third Quarter 2015 Results SAN JOSE, Calif., November 5, 2015 - Intermolecular, Inc. (NASDAQ: IMI) - a leader in engineered materials solutions - today announced results for its third quarter ended September 30, 2015 Third Quarter Fiscal 2015 Results Revenue for the third quarter of 2015 was $11.5 million, compared |
|
| November 6, 2015 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 2) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporatio |
|
| November 5, 2015 |
Results of Operations and Financial Condition 8-K 1 c241-20151105x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of I |
|
| November 5, 2015 |
Results of Operations and Financial Condition 8-K/A 1 imi-20151105x8ka.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or |
|
| November 5, 2015 |
EX-99.1 2 imi-20151105ex991eb9047.htm EX-99.1 Exhibit 99.1 Intermolecular Announces Third Quarter 2015 Results SAN JOSE, Calif., November 5, 2015 - Intermolecular, Inc. (NASDAQ: IMI) - a leader in engineered materials solutions - today announced results for its third quarter ended September 30, 2015 Third Quarter Fiscal 2015 Results Revenue for the third quarter of 2015 was $11.5 million, compared |
|
| August 11, 2015 |
8-K 1 imi-20150811x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco |
|
| August 6, 2015 |
Results of Operations and Financial Condition 8-K 1 imi-20150806x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco |
|
| August 6, 2015 |
20150806EX991 Exhibit 99.1 Intermolecular Announces Second Quarter 2015 Results SAN JOSE, Calif., August 6, 2015 - Intermolecular, Inc. (NASDAQ: IMI) - accelerating research and development (R&D) for advanced materials - today announced results for its second quarter ended June 30, 2015. Second Quarter Fiscal 2015 Results Revenue for the second quarter of 2015 was $11.0 million, compared to $9.9 m |
|
| July 27, 2015 |
Intermolecular 8-K (Current Report/Significant Event) imiCurrent folio8K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 1, 2015 |
EX-99.1 2 ex991to13d0773804206242015.htm JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including amendments thereto) with respect to the Common Stock, $0.001 par value, of Intermolecu |
|
| July 1, 2015 |
IMI / Intermolecular, Inc. / Raging Capital Management, LLC - SCHEDULE 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Intermolecular, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 45882D 10 9 (CUSIP Number) STEVE WOLOSKY, ESQ. OLSHA |
|
| July 1, 2015 |
Unassociated Document Exhibit 24 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints Allan J. |
|
| July 1, 2015 |
Exhibit 99.2 POWER OF ATTORNEY Know all by these presents, that each of the undersigned hereby constitutes and appoints Allan J. Young signing singly, the undersigned’s true and lawful attorney-in-fact to: 1. Execute for and on behalf of the undersigned all documents relating to the business of Raging Capital Management, LLC, including, but not limited to, all filings with the Securities and Excha |
|
| May 29, 2015 |
Submission of Matters to a Vote of Security Holders 8-K 1 c241-20150529x8k.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 27, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incor |
|
| May 7, 2015 |
EX-99.1 2 c241-20150506ex9910a26d9.htm EX-99.1 Exhibit 99.1 Intermolecular Announces First Quarter 2015 Results SAN JOSE, Calif., May, 2015 - Intermolecular, Inc. (NASDAQ: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its first quarter ended March 31, 2015. First Quarter Fiscal 2015 Results Revenue for the first quarter o |
|
| May 7, 2015 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 10, 2015 |
imiCurrent folio14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 10, 2015 |
DEFA14A 1 imi-20150527xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ◻ Check the appropriate box: ◻ Preliminary Proxy Statement ◻ Confidential, for Use of the Commission Only |
|
| March 19, 2015 |
IMI / Intermolecular, Inc. / ENTEGRIS INC - SCHEDULE 13G Passive Investment Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO §240. |
|
| February 27, 2015 |
IMI / Intermolecular, Inc. S-8 - - S-8 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTERMOLECULAR, INC. (Exact name of registrant as specified in its charter) Delaware 20-1616267 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3011 N. First Street San Jose, CA 95134 (A |
|
| February 17, 2015 |
IMI / Intermolecular, Inc. / Park West Asset Management LLC - SC 13G/A Passive Investment SC 13G/A 1 intermolsch13gam3dec312014.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* INTERMOLECULAR INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statem |
|
| February 17, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)1 Intermolecular, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D 10 9 (CUSIP Number) D |
|
| February 12, 2015 |
Results of Operations and Financial Condition 8-K 1 a8k-2014q4earningsrelease.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 12, 2015 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdi |
|
| February 12, 2015 |
EX-99.1 2 a8-k2014q4xex991.htm EXHIBIT 99.1 Exhibit 99.1 Intermolecular Announces Full Year and Fourth Quarter 2014 Results SAN JOSE, Calif., February 12, 2015 - Intermolecular, Inc. (NASDAQ: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its full year and fourth quarter ended December 31, 2014. Full Year 2014 Results For |
|
| February 11, 2015 |
IMI / Intermolecular, Inc. / Miller Lloyd I III - SC 13G Passive Investment SC 13G 1 v401249sc13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D109 (CUSIP Number) February 10, 2 |
|
| February 4, 2015 |
IMI / Intermolecular, Inc. / MUBADALA DEVELOPMENT CO PJSC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 ss415251sc13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 Intermolecular, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D 109 (CUSIP Number) December 31, 2014 (Date of Event Which Requires Filing of this Statement |
|
| December 30, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 19, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 20, 2014 |
IMI / Intermolecular, Inc. / Cmea Ventures Vi Lp - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 Amendment No. 2 INTERMOLECULAR, INC. (Name of Issuer) COMMON STOCK, $.001 PAR VALUE (Title of Class of Securities) 45882D109 (CUSIP Number) DECEMBER 31, 2014 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu |
|
| November 17, 2014 |
IMI / Intermolecular, Inc. / Presidio Partners 2014, L.P. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INTERMOLECULAR, INC. (Name of Issuer) COMMON STOCK, $.001 PAR VALUE (Title of Class of Securities) 45882D109 (CUSIP Number) NOVEMBER 10, 2014 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| October 31, 2014 |
EX-99.1 2 a8-k2014q3xex991.htm EXHIBIT Exhibit 99.1 Intermolecular Announces Third Quarter 2014 Financial Results SAN JOSE, Calif., Oct. 31, 2014 - Intermolecular, Inc. (Nasdaq: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its third quarter ended September 30, 2014. Revenue for the third quarter of 2014 was $10.9 million |
|
| October 31, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 31, 2014 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 31, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 14, 2014 |
3011 North First Street, San Jose, CA 95134 (408) 582-5700 / (408) 582-5401 fax Intermolecular Appoints Dr. Bruce McWilliams as President and Chief Executive Officer SAN JOSE, Calif. – October 13, 2014 - Intermolecular, Inc. (Nasdaq: IMI)— accelerating research and development for semiconductor and clean energy industries—today announced that Dr. Bruce McWilliams has been appointed President and Chief Executive Officer. David Lazovsky has resigned as President and Chief Execu |
|
| October 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 12, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 14, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 12, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| August 1, 2014 |
Exhibit 99.1 Intermolecular Announces Second Quarter 2014 Financial Results SAN JOSE, Calif., August 1, 2014 - Intermolecular, Inc. (Nasdaq: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its second quarter ended June 30, 2014. Revenue for the second quarter of 2014 was $9.9 million, a decline of 40% from $16.6 million in |
|
| August 1, 2014 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| June 2, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| May 20, 2014 |
IMI / Intermolecular, Inc. / Raging Capital Management, LLC Passive Investment SC 13G/A 1 sc13ga10773804204302014.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Intermolecular, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of S |
|
| May 19, 2014 |
SANDISK AND TOSHIBA TAKE EXCLUSIVE LICENSE TO INTELLECTUAL PROPERTY IN MEMORY TECHNOLOGY DEVELOPED WITH INTERMOLECULAR SAN JOSE, Calif. |
|
| May 19, 2014 |
8-K 1 a8-kxsandiskandtoshibaexer.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction |
|
| May 8, 2014 |
8-K 1 a8-kreductioninforce.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In |
|
| May 6, 2014 |
Exhibit 99.1 Intermolecular Announces First Quarter 2014 Financial Results Key Technologies for Advanced Memory and LED Near Customer Commercialization in 2014 SAN JOSE, Calif., May 6, 2014 - Intermolecular, Inc. (Nasdaq: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its first quarter ended March 31, 2014. Revenue for the |
|
| May 6, 2014 |
Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| April 18, 2014 |
TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 18, 2014 |
DEFA14A 1 a2014proxycoverpage.htm DEF 14A TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confident |
|
| April 9, 2014 |
8-K 1 a8-kxsjaggicompensationupd.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 5, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdicti |
|
| April 3, 2014 |
IMI / Intermolecular, Inc. / INTERMOLECULAR INC - SC 13G Passive Investment SC 13G 1 schedule13glazovsky2014.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d‑102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d‑1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d‑2 (Amendment No. )* INTERMOLECULAR, INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 4 |
|
| March 10, 2014 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G dated March 10, 2014 (including amendments thereto) with respect to the Common Stock of Intermolecular, Inc. This Joint Filing Agreement shall be filed as an Exh |
|
| March 10, 2014 |
S-8 1 s8registrationstatement-fe.htm S-8 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 INTERMOLECULAR, INC. (Exact name of registrant as specified in its charter) Delaware 20-1616267 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3 |
|
| March 10, 2014 |
Intermolecular 10-K (Annual Report) 10-K 1 a10k-20131231.htm 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2013 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to |
|
| March 10, 2014 |
IMI / Intermolecular, Inc. / Raging Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Intermolecular, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D 10 9 (CUSIP Number) Fe |
|
| February 27, 2014 |
Intermolecular Announces New Developments in the SanDisk/Toshiba Relationship EX-99.1 2 ex9918ksandisktoshiba.htm EXHIBIT Intermolecular Announces New Developments in the SanDisk/Toshiba Relationship SAN JOSE, Calif. - February 27, 2014 - Intermolecular, Inc. (NASDAQ: IMI) today announced that the development activity related to the Collaborative Development Program (“CDP”) agreement with SanDisk and Toshiba has reached its successful conclusion. “The objective of the CDP w |
|
| February 27, 2014 |
8-K 1 a8k-sandisktoshibafebruar.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdi |
|
| February 25, 2014 |
IMI / Intermolecular, Inc. / ATMI INC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2014 |
IMI / Intermolecular, Inc. / Cmea Ventures Vi Lp - SC 13G/A Passive Investment SC 13G/A 1 d675623dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Intermolecular, Inc. (Name of Issuer) Common Stock, $.001 par value per share (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 14, 2014 |
IMI / Intermolecular, Inc. / Park West Asset Management LLC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 interm13gam2.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* INTERMOLECULAR, INC. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 45882D109 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement) C |
|
| February 13, 2014 |
IMI / Intermolecular, Inc. / MUBADALA DEVELOPMENT CO PJSC - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 ss203130sc13ga.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment No. 1)* Under the Securities Exchange Act of 1934 Intermolecular, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 45882D 109 (CUSIP Number) December 31, 2013 (Date of Event Which Requires Filing of this Statement |
|
| February 10, 2014 |
IMI / Intermolecular, Inc. / U S Venture Partners IX L P - SC 13G/A Passive Investment SC 13G/A 1 v367479sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)* Intermolecular, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 45882D 109 (CUSIP Number) December 31, 2013 (Date o |
|
| February 6, 2014 |
8-K 1 a8kguardianxamendment3.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdictio |
|
| February 6, 2014 |
8-K 1 a8kgfamendment3.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In |
|
| February 6, 2014 |
Results of Operations and Financial Condition 8-K 1 a8-k2013q4earningsreductio.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2014 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdi |
|
| February 6, 2014 |
EX-99.1 2 a8-k2013q4xex991.htm EXHIBIT Exhibit 99.1 Intermolecular Announces Full Year and Fourth Quarter 2013 Results Company implements corporate restructuring to improve operations SAN JOSE, Calif., February 6, 2014 - Intermolecular, Inc. (NASDAQ: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its full year and fourth q |
|
| December 31, 2013 |
8-K 1 a8-kxguardianamendment.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdicti |
|
| December 30, 2013 |
8-K 1 a8-kxatmiamendment.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction o |
|
| December 30, 2013 |
8-K 1 a8-kxfirstsolaramendment.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 30, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdic |
|
| December 4, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 29, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 24, 2013 |
EX-99.1 2 a8-k2013x1024xex991.htm EXHIBIT Exhibit 99.1 Intermolecular Announces Third Quarter 2013 Financial Results Financial Results Ahead of Guidance, Internal R&D Pipeline Being Primed for Future CDP Growth SAN JOSE, Calif., October 24, 2013 - Intermolecular, Inc. (NASDAQ: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for |
|
| October 24, 2013 |
Results of Operations and Financial Condition 8-K 1 a8-k2013x1024xearningsrele.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 24, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdi |
|
| October 22, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 16, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 7, 2013 |
Financial Statements and Exhibits 8-K/A 1 a8-kaforrickneely.htm 8-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or |
|
| October 3, 2013 |
8-K 1 a8-kuctt.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 29, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpo |
|
| October 2, 2013 |
[Employee Proprietary Information and Inventions Agreement] August 22, 2013 C. Richard Neely, Jr. 259 Prince Street Los Gatos, CA 95032 Re: INTERMOLECULAR, INC. OFFER LETTER Dear Rick: INTERMOLECULAR, INC. (the “Company”) is pleased to offer you the position of Senior Vice President & Chief Financial Officer (CFO) of the Company, reporting to the CEO. You will be based at Company’s offices in San Jose, California. As the CFO, you will perform the duties cu |
|
| October 2, 2013 |
EX-99.1 3 ex991rickneelypressrelease.htm EXHIBIT INTERMOLECULAR NAMES SEMICONDUCTOR INDUSTRY VETERAN RICK NEELY CFO Mr. Neely Brings More than 30 Years of Financial and Operations Management Experience from Leading High-Tech Companies SAN JOSE, Calif. - October 2, 2013 - Intermolecular, Inc. (NASDAQ: IMI) today announced that it has named C. Richard (Rick) Neely, Jr. as the company’s chief financi |
|
| October 2, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 2, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 19, 2013 |
AMENDMENT TO WARRANT TO PURCHASE SHARES OF COMMON STOCK EX-4.1 2 ex41-amendmenttowarrant.htm EXHIBIT AMENDMENT TO WARRANT TO PURCHASE SHARES OF COMMON STOCK This Amendment to Warrant to Purchase Shares of Common Stock (this “Amendment”) is made and entered into as of the last date of signature of the parties below, and amends that certain Warrant to Purchase Shares of Common Stock issued on March 15, 2010 (the “Warrant”) by Intermolecular, Inc., a Dela |
|
| September 19, 2013 |
8-K 1 a8-kforwarrantamendments.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 17, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdi |
|
| August 20, 2013 |
8-K 1 a8k-russiapressrelease.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 20, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction |
|
| August 7, 2013 |
August 7, 2013 VIA EDGAR Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| August 2, 2013 |
8-K 1 a8-kreedinterimcfo.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of I |
|
| July 25, 2013 |
Exhibit 99.1 Intermolecular Announces Second Quarter 2013 Financial Results Early Stage CDP with Tier One Customer Marks Entry into $80 Billion Display Market SAN JOSE, Calif., July 25, 2013 - Intermolecular, Inc. (Nasdaq: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its second quarter ended June 30, 2013. Revenue for th |
|
| July 25, 2013 |
Results of Operations and Financial Condition 8-K 1 a8-kearningsq22013.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 25, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of In |
|
| June 18, 2013 |
8-K 1 globalfoundriesamendment.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 1, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction |
|
| June 7, 2013 |
8-K 1 a8-keidelman.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 4, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorpora |
|
| June 3, 2013 |
EX-10.1 2 svbintermolecularxloanand.htm EXHIBIT LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) dated as of May , 2013 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and INTERMOLECULAR, INC., a Delaware corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties |
|
| June 3, 2013 |
8-K 1 a8-ksvbagreement.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incor |
|
| May 31, 2013 |
8-K 1 a8-kvotingresults.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 29, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Inco |
|
| April 25, 2013 |
Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 25, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 25, 2013 |
Exhibit 99.1 Intermolecular Announces First Quarter 2013 Financial Results Recent CDP and IP Agreements with Micron and Epistar -Further Expanding in Memory, and Diversifying into LED SAN JOSE, Calif., April 25, 2013 - Intermolecular, Inc. (NASDAQ: IMI)-accelerating research and development (R&D) for semiconductor and clean energy industries-today announced results for its first quarter ended Marc |
|
| April 17, 2013 |
8-K 1 a8-kmicronapril2013.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of |
|
| April 17, 2013 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2013 Intermolecular, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-35348 20-1616267 (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| April 17, 2013 |
TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 17, 2013 |
DEFA14A 1 a2013proxy.htm DEFA14A TABLE OF CONTENTS Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for |
